BioTech Medical Exhibiting at ISSA/INTERCLEAN 2009
SAN DIEGO, CA, October 5, 2009 – PURE Bioscience (NASDAQ: PURE) and BioTech Medical LLC today announced that BioTech Medical will be exhibiting at the annual ISSA/INTERCLEAN® trade show being held this week in Chicago. BioTech Medical’s booth, number 2042, will feature SpectraSan24, a revolutionary disinfectant powered by PURE’s silver dihydrogen citrate (SDC) antimicrobial technology.
Andrea L. Goren, Executive Director of BioTech Medical LLC, stated, “We are focused on building brand recognition through public relations, marketing and professional endorsements as a foundation for nationwide sales of SpectraSan24 in dozens of business categories in the commercial, institutional and retail marketplace. This trade show comes at a critical point in our marketing strategy as we to continue to educate the industry about the unique benefits of SpectraSan24 as well as capture direct sales and establish additional downline distribution relationships.”
As the worldwide cleaning industry association, ISSA’s global membership includes more than 5,500 distributor, manufacturer, building service contractor, and in-house service provider companies. ISSA offers the industry's largest cleaning shows around the world; a vast array of educational videos and resources; networking on local, national, and international levels; industry management standards; legislative and regulatory services; and industry news specifically focused on the world's cleaning community.
Jefferey Donnell, PURE Bioscience’s Vice President of Business Development, commented, “BioTech Medical launched a successful public relations campaign that so far resulted in coverage of SpectraSan24 in more than 30 trade publications during the last three months. The PR program, combined with the exhibit booth at ISSA/INTERCLEAN demonstrates BioTech Medical’s dedication to promoting SpectraSan24 as a leading brand in the commercial and institutional markets.”
SpectraSan 24’s broad spectrum power completely and rapidly eliminates bacteria, fungi and viruses, including Influenza A. SpectraSan 24 also carries a 30-second kill time on standard indicator bacteria, a 24-hour residual kill on standard indicator bacteria, a 2-minute kill time on some resistant strains of bacteria, a 10-minute kill time on fungi, a 30-second kill time on HIV Type I, and 10-minute kill times on other pathogenic viruses. These claims distinguish the efficacy of SpectraSan 24 from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings. Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, SpectraSan 24 is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products.
About BioTech Medical, LLC
BioTech Medical LLC is a North Canton, Ohio based division of privately-held SCI Industries, a leading international marketing company. SCI distributes hundreds of diversified products around the world and has established its success through product innovation and multi-channel marketing. BioTech Medical’s multiple business segments are each focused on the distribution of innovative healthcare products, including the SDC-based SpectraSan24 and Cruise Control hard surface disinfectants. For more information, please visit www.spectrasan.com.
About PURE Bioscience
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project,” "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.